Nektar Therapeutics Current Income Tax Expense (Benefit)
Nektar Therapeutics (NKTR) reported Current Income Tax Expense (Benefit) of -$202.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-13
- Nektar Therapeutics current income tax expense (benefit) for fiscal 2025 was -$202.00K.
- Nektar Therapeutics current income tax expense (benefit) for fiscal 2024 was -$229.00K.
- Nektar Therapeutics current income tax expense (benefit) for fiscal 2023 was -$60.00K, a 111.83% decline from fiscal 2022.
- Nektar Therapeutics current income tax expense (benefit) for fiscal 2022 was $507.00K, a 23.07% decline from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$202.00K 10-K · filed 2026-03-13 |
| 2024-12-31 | -$229.00K 10-K · filed 2026-03-13 |
| 2023-12-31 | -$60.00K 10-K · filed 2025-03-14 |
| 2022-12-31 | $507.00K 10-K · filed 2024-03-05 |
| 2021-12-31 | $659.00K 10-K · filed 2024-03-05 |
| 2020-12-31 | $529.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | $634.00K 10-K · filed 2022-03-01 |
| 2018-12-31 | $1.32M 10-K · filed 2021-02-26 |
| 2017-12-31 | $581.00K 10-K · filed 2020-02-28 |
| 2016-12-31 | $991.00K 10-K · filed 2019-03-01 |
| 2015-12-31 | $528.00K 10-K · filed 2018-03-01 |
| 2014-12-31 | -$481.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $1.84M 10-K · filed 2016-02-29 |
| 2012-12-31 | $893.00K 10-K · filed 2015-02-26 |
| 2011-12-31 | $922.00K 10-K · filed 2014-02-27 |
| 2010-12-31 | $701.00K 10-K · filed 2013-03-01 |
| 2009-12-31 | -$198.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |